The UK and US have hammered out a major commercial pact that will maintain no duties on British pharmaceutical exports entering the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to raise funding on drugs through the public health system. This move secures that tariffs on these crucial exports will be held at nothing for a period of the next three years.
This deal is in response to recent threats to significantly raise duties on patented drug imports, with potential rates mentioned as high as one hundred percent.
"This arrangement between the UK reinforces the global environment for cutting-edge drugs and brings long-overdue equity to American-British pharmaceutical trade," a release said.
Commercial Importance
Drugs represent one of the UK's biggest exports to the America, which is easily the primary market for large UK drugmakers.
Statistics indicate that in the year leading up to last September, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This amount accounted for 17.4% of British export trade in that period.
"This agreement protects jobs, boosts capital expenditure and facilitates the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary remarked.
Key British Pledges
The agreement involves several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it considers new medicines to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to increase total public funding on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, repayments exceeded twenty percent.
Broader Context
The deal takes place against a protracted row between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
These tensions were intensified by arguments that US consumers were paying significantly more for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been halted or cancelled, while major expansions have been directed toward US facilities.
The Science Minister acknowledged that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had shrunk as a percentage of its total funding over the last ten years.
